The MyOwnMed Platform provides direct, ongoing connectivity between healthcare, study or management personnel, and patients with our HCP portal and mobile app. We’re supporting health management and clinical trial partners with our HIPAA and GDPR compliant cloud-based technology.
Client
Drexel University College of Medicine with National Institute of Allergy and Infectious Diseases (NIAID), Boston Children’s Hospital
Participants
COVID-19 Patients
Status
Launched July, 2020
THE STUDY
Long-term consequences of the COVID-19 infection and recovery are still unknown, and are the subject of a new study, IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC). The MyOwnMed mobile app containing a COVID-19 symptom tracker and other life-impact surveys is in use over the course of this ground-breaking one-year follow-up study of COVID-19 patients post-hospitalization.
SNAPSHOT
- First controlled study correlating COVID-19 symptoms and patient-reported outcomes with immune status
- Ability to support patients at home during COVID-19 recovery
- Nationwide multi-site distributed data collection direct from recovering COVID-19 patient
- LANGUAGES: English, Spanish, Chinese, Russian
- MODULE: PROMIS Survey API
Client
University Medical Center Utrecht
Participants
Children (Parents/Caregivers)
Status
Launched March, 2016
Ongoing
THE STUDY
Reuma2Go is a mobile app and provider portal built on the MyOwnMed Platform supporting clinical research and care management in children with Juvenile Idiopathic Arthritis (JIA). After more than four years in use with hundreds of children, Reuma2Go has demonstrated long-term success using the MyOwnMed Platform for continuous monitoring, increased convenience for patients and families, and better insights into their condition.
SNAPSHOT
- More than 400 participants over 4 years
- 96% use the app 3-30min/week
- 95% report app as being useful
- 68% experience better insight into their health conditions
- 32% experience improved health outcomes
- Remotely monitor and predict relapse and remission with mobile PRO tools
- LANGUAGES: English, Dutch
- MODULE: Profile Management
“[UMCU and MyOwnMed] are creating a better view on arthritis. This will help us partner with doctors [and] share decision-making for medications and clinical follow up."
prof. dr. N.M. (Nico M.) Wulffraat
Professor of Pediatric Rheumatology, University Medical Center, Utrecht, The Netherlands
Client
Immune Tolerance Network and Mt. Sinai Medical Center
Participants
Infants/Mothers
Status
Launched November, 2018
Ongoing
THE STUDY
The goal of the ACTIVATE study is to look at how differences in the microbiome of a baby may protect, or put a baby at risk, for allergic problems. To do this, the study will measure whether wiping babies born by C-section with their mother’s vaginal fluids (which contains potentially beneficial bacteria; referred to as “vaginal seeding”) right after birth will lower the risk of developing positive allergy tests at one year of age. The MyOwnMed Platform provides the app tool to monitor moms and their baby’s allergies for their first year. Our Platform also alerts study staff when women go into labor providing a way to meet the moms at the hospital and capture on-the-spot data.
SNAPSHOT
- All moms and study personnel successfully connected at the hospital during births (including the critical time during the NYC COVID-19 outbreak)
- 90%+ participation to completion of maternal and infant surveys
- MODULE: Specimen Collection, Tracking
- MODULE: Real-Time Alerts for Study Staff
Client
Parker Institute for Cancer Immunotherapy
Participants
Cancer Patients
Status
Launched July, 2019
Completed
THE STUDY
Cancer immunotherapy or checkpoint inhibitors are among the most promising new cancer therapies. By activating T-cells, they can attack cancer cells but this can also result in development of autoimmunity. PICI is studying autoimmune conditions following check-point inhibition treatment of cancer. Through partnerships with the National Cancer Care Alliance and Precision Cancer Research, PICI is collecting clinical data and blood samples from patients during their cancer treatment with immunotherapy. The MyOwnMed Platform is then used to monitor autoimmune symptoms so additional samples can be taken and studied.
SNAPSHOT
- Cost-effective from pilot to large-scale
- MODULE: PROMIS Survey API
- ADD-ON: Wearables API (FitBit®)
Client
University of Arizona, Center for Innovation in Brain Science
Participants
Alzheimer’s Patients
Status
Launched September, 2019
THE STUDY
This study is a national multi-site Phase 2 clinical trial to determine the effectiveness of Allopregnanolone, (ALLO), as a treatment for individuals with early-stage Alzheimer’s disease.
SNAPSHOT
- MODULE: Profile management for patient and caregiver reported outcomes
- ADD-ON: Transportation API (e.g. Uber®)
- ADD-ON: Wearables API (e.g. FitBit®, Apple® Health)
"The MyOwnMed team worked closely with us to develop a novel strategy for Alzheimer's patients and their caregivers. [The team] was amazing and generated progress in record time that allowed us to reach our goal. Data derived from the MyOwnMed Platform has generated insights [...] into outcomes relevant to therapeutic efficacy. Importantly, the MyOwnMed group is an innovative team with exceptional brains and compassion committed to advancing precision medicine and health care in real people, in real time."
Roberta Diaz Brinton, Ph.D.
Director, Center for Innovation in Brain Science Professor Departments of Pharmacology and Neurology College of Medicine, University of Arizona
Client
Drexel University College of Medicine
Participants
Students
Educators
Employees
Status
Launched June, 2020
THE STUDY
Drexel University (Drexel) and My Own Med, Inc. (MyOwnMed) have partnered to develop and implement a Health Tracker mobile app to collect and monitor user data in support of the safe transition of employees and students back to work and school amidst the COVID-19 pandemic.
SNAPSHOT
- Scalability built to support entire Drexel University community of 35,000+
- Pioneering back-to-school/back-to-work academic collaboration
- MODULE: Patient Check-In for Self Certification
We look forward to working with MyOwnMed and harnessing our expertise in infectious diseases to create digital tools that can help ensure the health and safety for our return to campus programs.
Charles B. Cairns, MD, FACEP, FAAEM, FAHA
Walter H. and Leonore Annenberg Dean and Senior Vice President of Medical Affairs | Drexel University’s College of Medicine
Client
Janssen Pharmaceuticals, Inc.
Participants
Children (Parents/Caregivers)
Status
Launched October 2019. Paused
THE STUDY
Crocus is a randomized controlled study of a new antiviral, for early childhood respiratory syncytial virus, requiring the ability to identify children with respiratory infections in the community. MyOwnMed assisted in reducing recruitment barriers with our ECOS Mobile digital app for healthy families, tracking child’s symptoms if they became ill, enabling action within a specific time frame.
SNAPSHOT
- Hundreds of invitations sent with mobile QR codes for app download
- 8 out of 10 focus group score for the ECOS Mobile app with Johnson & Johnson
- Significantly increased screening from 1 to 29, with six eligible patients at one site within three weeks
- ADD-ON: QR code for app download
Client
University of Arizona Health Sciences Center
Participants
Mental Health Patients
Status
Launched April, 2018
THE STUDY
EPICenter is a community mental health program offering specialized treatment fo persons early in the course of psychotic illness. The MyOwnMed ECOS Platform is in use to support in home monitoring of psychosis and integrate it with in-clinic assessment data to provide a comprehensive continuous solution for supporting adolescent and young adults with serious mental illness.
SNAPSHOT
- Personalized goal setting is built into the mobile app so that patients can self-monitor and track with their goals
- MODULE: Instant support alert systems for family and health care providers